{"id":"W2175453042","doi":"10.1007/s10549-015-3633-7","title":"Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial","year":2015,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Medical Research Council; Eisai; Celgene","keywords":"Capecitabine; Medicine; Eribulin; Metastatic breast cancer; Internal medicine; Nausea; Breast cancer; Quality of life (healthcare); Randomized controlled trial; Oncology; Cancer; Surgery; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001294046,0.0004667398,0.002511417,0.0004333764,0.00009663305,0.00004662913,0.0001721908,0.00008649415,0.0006234852],"category_scores_gemma":[0.00005621547,0.0002392617,0.00004271992,0.001221203,0.0004844525,0.0003300197,0.00007063529,0.0002888269,0.000002536324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001942414,"about_ca_system_score_gemma":0.005519331,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.122247,"about_ca_topic_score_gemma":0.1204783,"domain_scores_codex":[0.9951771,0.001301551,0.001126207,0.0007750119,0.0007803199,0.0008398286],"domain_scores_gemma":[0.9971322,0.0003498573,0.0003941934,0.0003761529,0.0007221677,0.00102539],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8580164,0.02413283,0.06592083,0.0001234081,0.001244318,0.0002132398,0.0007134143,0.00005630499,0.00002976229,0.00001029407,0.00005523575,0.04948397],"study_design_scores_gemma":[0.8900327,0.04367922,0.06474781,0.0005063728,0.0002522218,0.00003513648,0.0002246303,0.0001935647,0.00004624186,0.0000147956,0.00003027196,0.0002370145],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826447,0.001674228,0.000002616411,0.003377606,0.00005272502,0.01067776,0.001496199,0.00002640479,0.00004774165],"genre_scores_gemma":[0.9922891,0.00133617,0.0002256257,0.0001070058,0.00004950371,0.004805111,0.0004121136,0.00005899358,0.0007163657],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04924695,"threshold_uncertainty_score":0.9791057,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1701282498210228,"score_gpt":0.486875781200225,"score_spread":0.3167475313792022,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}